Surface-functionalisation of Zr-Fumarate MOF for selective cytotoxicity and immune system compatibility in nanoscale drug delivery. ACS Abstract Metal-organic frameworks (MOFs), network structures wherein metal ions or clusters link organic ligands into porous materials, are being actively researched as nanoscale drug delivery devices (DDSs) as they offer tuneable structures with high cargo loading that can easily be further functionalized for targeting and enhanced physiological stability. The excellent biocompatibility of Zr has meant that its MOFs are amongst the most studied to date, in particular the archetypal Zr terephthalate UiO-66. In contrast, the isoreticular analogue linked by fumarate (Zr-fum) has received little attention, despite the endogenous linker being part of the Krebs cycle. Herein, we report a comprehensive study of Zr-fum in the context of drug delivery. Reducing particle size is shown to increase uptake by cancer cells while reducing internalisation by macrophages, immune system cells that remove foreign objects from the bloodstream. Zr-fum is compatible with defect-loading of the drug dichloroacetate, as well as surface modification during synthesis, through coordination modulation, and postsynthetically. DCA-loaded, PEGylated Zr-fum shows selective in vitro cytotoxicity towards HeLa and MCF-7 cancer cells, likely as a consequence of its enhanced caveolae-mediated endocytosis compared to uncoated precursors, and it is well tolerated by HEK293 kidney cells, J774 macrophages, and human peripheral blood lymphocytes.
Introduction
The requirement for new cancer treatments is driven by increases in the diagnosed cases of cancer, the side effects of most available therapeutics, and the resistance of some tumours towards them. [1] [2] [3] Interest in drug delivery systems (DDSs) is increasing, with the ultimate aim of selectively targeting cancer cells with nanoscale "Trojan horses" capable of delivering therapeutic cargo directly to sites of disease. [4] [5] However, clinical application of DDSs faces drawbacks such as poor drug loading capacity, 6 fast drug release kinetics, 7 aggregation in the bloodstream, 8 non-specific biodistribution or accumulation in the body 9 and, in some cases, toxicity. 10 Developing model DDSs and methodology for their surface modifications, with the aims of controlling their physical properties and understanding the correlation between the former and their therapeutic activity, is of vital importance to ultimately lead to the design of novel DDSs. 11 Among these drug delivery devices, metal-organic frameworks (MOFs) [12] [13] a new generation of highly porous, crystalline structures comprised of organic and inorganic componentshave emerged as an alternative to combine the most attractive properties of organic (biocompatibility, targeted bio-distribution) [14] [15] and inorganic (high drug loadings, biostability) [16] [17] DDSs, making MOFs highly promising candidates to overcome the problems that nanomedicine is currently facing. [18] [19] [20] Zirconium-based MOFs have recently acquired significant interest as potential DDSs, as they are generally more thermally, mechanically and chemically stable than other MOF systems but will still degrade slowly under physiological conditions, [21] [22] while at the same time Zr has good biocompatibility 23 and they are amenable to postsynthetic modification. 24 For example, the Zr terephthalate MOF UiO-66, 25 where UiO stands for University of Oslo, and other MOFs of the UiO isoreticular series with ideal formula [Zr 6 O 4 (OH) 4 L 6 ] n , 26 have been postsynthetically modified with a number of surface moieties, including poly-Nisopropylacrylamide (PNIPAM), [27] [28] poly(ethylene glycol) (PEG), 29 DNA sequences, [30] [31] small interfering RNA (siRNA), 32 phospholipid bilayers, 33 L-dopamine, 34 and anticancer targeting units 35 among others. Surface coatings have been proven to improve simulated physiological stability, colloidal dispersion and drug release kinetics, among other properties.
While UiO-66 and the more porous MOFs of the UiO-66 series of MOFs have received widespread attention as potential DDSs, 26, 36 application of the isoreticular MOF composed of the endogenous fumarate linker are rare. 37 So-called Zr-fum ( Figure 1 ) has a similar structure to UiO-66, but its porosity is reduced compared to the rest of the series (S BET ~800 m 2 g -1 ) as the fumarate linker, an intermediate of the Krebs cycle, is shorter in length. 38 Zrfum can be synthesised in water, [38] [39] and has requisite stability for application in water adsorption 40 and harvesting, 41 catalysis, 42 and aqueous fluoride sequestration. 43 The potential application of Zr-fum nanoparticles of 83 ± 14 nm size as a DDS has been studied by Lachet and co-workers, 37 by coordinating various pro-apoptotic peptides and a cytochrome c protein (CytC) to the external surface of the MOF using the imidazole groups of terminal oligohistidine residues (His-tags). The coating was proven to be stable at pH 7.4 in HEPES buffered glucose (HBG), while partially released at pH 5, and completely cleaved at pH 3. Between 20 and 30 fold-increases in the internalisation of the various peptides by HeLa cervical cancer cells when attached to Zr-fum were observed; increases in cytotoxicity towards HeLa cells occur when pro-apoptotic peptides are delivered by the MOF, whereas free peptides are not cytotoxic as they cannot efficiently enter the cell. Additionally, the dye resorufin has been postsynthetically encapsulated in Zr-fum nanoparticles, followed by coating with galactosylamine, and used for intracellular imaging with no appreciable in vitro cytotoxicity towards FL83B and HepG2 cells. 44 These promising results demonstrate the requirement for a systematic study into the functionalization, stability, degradation, and cytotoxicity of Zr-fum to assess its general performance as a DDS in vitro.
The coordination modulation process, 45 in which monodentate ligands (modulators) are introduced to MOF syntheses and compete with the multidentate linkers for the metal coordination sites, has been widely used to control the particle size of MOFs [46] [47] and to enhance their physical properties, such as crystallinity and porosity. 48 The addition of modulators to synthesis of Zr MOFs is known to induce defects, such as missing clusters and linkers, and also install functionality on particle outer surfaces. 28, [49] [50] This process has been widely studied for UiO-66, and modulator incorporation has been found to be pK a dependent. 51 While modulation is known to control the particle size of Zr-fum, [38] [39] the MOF has not received special attention for defect engineering.
We have recently exploited this phenomenon to load an anticancer metabolic target, dichloroacetic acid (DCA), at defect sites within the bulk of Zr MOFs of the UiO-66 family during synthesis. 49 These defects enhance their porosity, which can be used to store a second anticancer drug, 5-fluorouracil (5-FU), resulting in dual drug loaded MOFs. The low pK a of DCA, together with its small size, ensures high incorporation (ca. 20% w/w) even in the presence of other modulators. [28] [29] Incorporation of both the cancer targeting folic acid (FA), and functionalised modulators, such as p-azidomethylbenzoic acid (L1), which can be further transformed by click chemistry, allow the assembly of surface functionalised, drug loaded UiO-66 nanoparticles which exhibit selective anticancer cytotoxicity.
Herein, we extend these surface functionalization protocols to Zr-fum, aiming to develop protocols for the control of (i) particle size, in order to study the size dependence of Zr fumarate on its physical properties (i.e. colloidal dispersion and phosphate stability) and on its cellular uptake by cancer cells and macrophages, and (ii) surface chemistry, to find any correlation with physical properties and in vitro performance, with the ultimate aim of assessing the potential for in vivo application of Zr-fum.
Results and discussion
Particle Size Control. The cellular internalisation pathways by which nanoparticulate DDSs are internalised are size dependent. [52] [53] [54] [55] Nano-devices are often internalised by eukaryotic cells through active transport such as endocytosis, although if small enough (<20 nm) DDSs can be internalised by passive diffusion. Among endocytosis pathways, the most studied are receptor-mediated endocytosis (i.e. caveolae or clathrin-mediated), 55 non-mediated endocytosis, and macropinocytosis. 56 It has been reported that DDSs internalised through the caveolae-mediated route could be more successful in delivering their cargo into the cytosol, due to endosomal escape through DDS encapsulation in caveosomes. 57 Macrophages, the cells responsible for removing foreign bodies from the blood current, usually internalise matter through phagocytosis. 58 To study how size affects the internalisation of Zr-fum by cancer cells and macrophages, crystalline ( Figure 2a ) nanoparticles of different sizes were synthesised utilising two different metal precursors, ZrCl 4 and ZrOCl 2 ·8H 2 O, with acetic acid as a modulator (See SI, Section S2). The large sample, Zr-fum (b), where b stands for big, is 168 ± 24 nm in diameter, as determined by SEM ( Figure 2b ), while Zr-fum (s), where s stands for small, is 23 ± 11 nm in size ( Figure 2c ), explaining the broadening of reflections in its powder X-ray diffraction (PXRD) pattern. Full characterisation (SI, Section S4.1)including FTIR spectroscopy, thermogravimetric analysis (TGA) and N 2 adsorption and desorption isothermsconfirmed the samples to be thermally stable and porous (S BET = 865 m 2 g -1 and 596 m 2 g -1 for Zr-fum (s) and Zr-fum (b) respectively). The pore volume of Zr-fum (s) at 0.98 p/p 0 (0.978 cm 3 g -1 ) compared to Zr-fum (b) (0.364 cm 3 g -1 ) suggests a high degree of defectivity, although it is possible this is filling of interparticle space between the very small nanoparticles.
Dynamic light scattering (DLS) measurements were performed in water ( Figure 2d ). Zr-fum (s) displays aggregates of size approximately 75 nm, while Zr-fum (b) forms aggregates of around 300 nm. This small amount of aggregation is in good agreement with the previous report from Lachelt and co-workers, 37 where nanoparticles of 83 ± 14 nm (SEM) showed aggregation in DLS measurements to 132 nm (ethanol) and 182 nm (water). the smaller analogue degrades with a two-step profile, with a slower rate during the first 3 h (releasing 20% vs 45% for the bigger analogue). Interestingly, Zr-fum seems to be more stable towards phosphate-induced degradation than UiO-66, which releases ~80% of its linker after a few hours. 28 This is possibly a consequence of the lower pK a of fumaric acid compared to terephthalic acid resulting in a more stable metal-carboxylate bond, and thus enhancing the competition between free phosphates and carboxylates for the coordination to the Zr clusters.
To monitor cellular uptake, a carboxylate containing fluorescent molecule, calcein, was postsynthetically loaded into the samples. Calcein is not able to efficiently cross the cell membrane due to its hydrophilicity (logP = -4), 59 and so it is an excellent probe for the cellular internalisation of MOFs. 60 Calcein loading in cal@Zr-fum (s) was considerably higher (16.8% w/w) than for cal@Zr-fum (b) (3.4% w/w), presumably as a consequence of thes higher degree of defects and greater external surface-to-bulk ratio of the former compared to the latter. It has been previously reported for UiO-66 that, due to the size of calcein, the molecule is not able to efficiently penetrate the porosity of the MOF, and so it is most likely to be coordinated to Zr clusters at the outer surface and at defect sites through its carboxylate groups. 29 Zr-fum has a smaller pore window than UiO-66; 25, 38 TGA and FTIR measurements confirm that external surface loading also occurs for Zr-fum (SI, Section S4.2.).
Fluorescence assisted cell sorting (FACS) was used to monitor the cellular internalisation of the cal@MOFs (SI, Section S3), showing that the smaller cal@Zr-fum (s) was more efficiently internalised by HeLa cervical cancer cells (by a factor of 2.3), while cal@Zr-fum (b) was better internalised by J774 macrophages (by a factor of 1.6) ( Figure 3a ). Importantly, cal@Zr-fum (s) was able to deliver calcein into HeLa cells with a 20-fold increase compared to free calcein, which is considerably higher than previously found for cal@UiO-66 (5-10 fold increase). 28, 61 The use of inhibitors of certain endocytic pathways 28 chains. 29 To assess the contribution of non-active transport (i.e. passive diffusion) a control in which the cells were incubated with the MOFs at 4 ºC, a temperature at which most cellular functions are attenuated, 62 was performed and normalised to the cellular internalisation at 37 ºC ( Figure 3b ). The higher degree of internalisation of cal@Zr-fum (s) at 4 ºC (37 ± 1% vs 21 ± 1% for cal@Zr-fum (b)) indicates that passive diffusion could play some role in its cellular internalisation, although not to the same extent as active transport, which is of greater importance. Passive diffusion can also facilitate cytosolic localisation, which is favourable for drug delivery. 63 Surface Functionalisation. Due to these encouraging resultsparticle size reduction resulting in an enhancement in internalisation cancer cells internalisation, with possible passive diffusion, and a decrease in macrophage recognition -cal@Zr-fum (s) was selected for further study. Surface modifications with folic acid (targeting) 64 and PEG (dispersion, immune system avoidance) 65 were attempted during synthesis and postsynthetically (Scheme 1), following our previously reported protocols (SI, Section S2). 28 ºC decreased cell internalisation of cal@Zr-fum-L1 (compared to incubation at 37 °C) to similar levels as its precursor cal@Zr-fum (s) (33 ± 3% uptake vs 37 ± 1%), whereas the effect was less pronounced for the PEGylated (62 ± 4% uptake) and folate-coated MOFs (79 ± 5% uptake), indicating a higher contribution of non-active transport (Figure 5b ). It is important to consider that although the average particle size distribution of Zr-fum (s) (23 ± 11 nm) is slightly above the size expected to allow passive diffusion through the cell membrane, a considerable portion of the nanoparticles is smaller than 20 nm ( Figure S5 ), and so, after surface coating with more lipophilic moieties, the passive diffusion of this population of smaller nanoparticles could be enhanced. 67 29 These results suggest that coating different MOFs with PEG chains can induce uptake through caveolae mediated-endocytosis, seemingly without a major size effect. On the other hand, in contrast to cal@UiO-66-FA, which was determined to be partially internalised by caveolae-mediated endocytosis, 28 the internalisation of cal@Zr-fum-FA (s) was not inhibited by nystatin. This may be a consequence of passive diffusion still occurring in the presence of nystatin due to the small particle size, but this would also be expected to occur when the clathrin-mediated pathway is inhibited by chlorpromazine.
Drug Delivery. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (PDK)
inhibitor. 68 Thus, DCA shifts cancer cell metabolism from glycolysis back to glucose oxidation by pyruvate dehydrogenase re-activation, unlocking cancer cells from a state of apoptosis resistance without affecting growth of healthy cells. [69] [70] However, the hydrophilic nature of DCA means it does not efficiently cross the cell membrane, 71 resulting in limited ability to reach its target and rapid clearance from the bloodstream. 72 Consequently, DCA has half maximum effective concentration (EC 50 ) values in the millimolar range, 73 meaning that doses three orders of magnitude higher than for current anticancer drugs are needed to induce a similar therapeutic effect. Nevertheless, in vitro studies have shown remarkably lower resistance factors towards DCA compared to other anticancer therapeutics, [73] [74] and DCA has also been shown to enhance the anticancer effect of well-known drugs such as 5fluorouracil and cisplatin. 73, [75] [76] While DCA is not currently under clinical use as an anticancer drug, several clinical trials have shown that DCA treatment induces significant tumour remission with very low side effects and toxicity compared to other therapeutics. [77] [78] [79] [80] DCA's excellent therapeutic activity combined with its poor cellular internalisation makes it a highly informative mechanistic probe to study the potential effect of MOFs as DDSs, as a substantially enhanced cytotoxicity will be a consequence of efficient internalisation of the MOFs and the subsequent release of their cargo into the cytosol.
In order to study the effect of particle size and surface chemistry on therapeutic activity, dichloroacetic acid was introduced as a modulator of Zr-fum synthesis, with or without the co-modulation of folic acid, to prepare DCA@Zr-fum (s) and DCA@Zr-fum-FA (CM), respectively (Scheme 3). Figure 6 shows the typical analytical techniques used to monitor DCA incorporation into DCA@Zr-fum (s) (see SI Section S6 for full characterisation of other samples). DCA is an effective modulator of Zr MOFs, with crystallinity retained but weak broad reflections indicating small particle size and/or defectivity (Figure 6a ). As a consequence of the low pK a of DCA (~1.4), its incorporation into the MOFs at defect sites was considerable (~20% w/w).
Loading can be assessed by thermogravimetric analysis (TGA, Figure 6b ) so long as its thermal decomposition does not overlap with surface functionality, and confirmed by ICP-MS analysis of Cl content (20.4% w/w for DCA@Zr-fum (s)). FT-IR spectra (Figure 6c ) also showed its presence within the MOF samples, with a shifting of the DCA carbonyl stretch from ca. 1730 cm -1 to 1650 cm -1 indicating its coordination to the Zr clusters. The particle size distributions, determined by SEM ( Figures S43-S46 h. The cytotoxicity of the PEGylated sample is possibly a consequence of its partial internalisation through caveolae-mediated endocytosis, 57 while it is significantly more cytotoxic towards HeLa than its UiO-66 analogue, 29 suggesting that Zr-fum is more effective at delivering DCA into the cells. It is important to take into account that although DCA@Zrfum (s) has a particle size distribution (29 ± 9 nm) similar to Zr-fum (s) (23 ± 11 nm), the fraction of nanoparticles smaller than 20 nm is less significant, as can be observed in the particle size distribution histograms ( Figure S46 ), meaning that passive diffusion may be less prevalent for this sample. DCA@Zr-fum-FA (CM) is bigger in size (ca. 100 nm), comparable to cal@Zr-fum (b), which was proven not to be internalised significantly by HeLa cells compared to the smaller analogues. Additionally, folate-coated cal@Zr-fum-FA (PS) did not show any significant caveolae-mediated uptake, which seems to be key to efficient DCA cytotoxicity. The PEGylated MOF has the lowest DCA loading (12.1% w/w), thus enhancing the therapeutic effect of the free drug by a factor of over 200 28 might indicate potential problems towards in vivo application if significant accumulation is observed. A similar effect has been seen previously for DCA delivery with analogous PEGylated UiO-66 at the same dosage, 28 and overall, DCA@Zr-fum-L1-PEG2000 (s) seems to be more efficient at enhancing the selective anticancer cytoxicity of DCA than its UiO-66 analogue (SI, Figure S71 ). The complement cascade activation (C3 and C4) was investigated upon incubation of blood plasma from three human donors with the MOFs. The complement cascade is a part of the immune system which eliminates foreign pathogens, and its activation usually results in activation of phagocytic cells and inflammation. 81 In Figures 8b and 8c 
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Conclusions
In the context of nanoscale drug delivery, the UiO series MOF linked by the endogeneous fumarate ligand, Zr-fum, has been shown to be amenable to size-controlled synthesis and surface modification by a number of protocols. The anticancer probe molecule DCA has been introduced to Zr-fum as a modulator during synthesis, with payloads of 20% w/w stored at defect sites, and the samples could also be surface modified without major DCA leakage.
Cellular internalisation of Zr-fum was found to be size dependent; the smaller sample, Zr-fum (s) (~23 nm) was significantly better internalised by HeLa cervical cancer cells compared to the bigger analogue Zr-fum (b) (~170 nm), yet the latter was more internalised by macrophages, suggesting liver and spleen accumulation could be reduced by effective size refinement through in vitro studies previous to in vivo trials. Additionally, the efficient internalisation of the smaller MOFs at 4 ºC indicates that passive diffusion could play an important role in cellular uptake. While PEGylation of Zr-fum can induce caveolae-mediated endocytosis, as has been found to be the case for UiO-66, 29 were non-toxic towards a series of non-cancerous cell lines, including J774 macrophages, HEK293 kidney cells and lymphocytes isolated from the blood of human donors; some residual cytotoxicity of DCA@Zr-fum-L1-PEG2000 (s) towards kidney cells at high concentrations was the only concern. Only the PEGylated DCA@Zr-fum-L1-PEG2000 (s) induced cytotoxicity towards HeLa cancer cells, stopping all proliferation when incubated at 0.5 mgmL -1 (ca 0.06 mgmL -1 DCA) indicating that internalisation through the caveolaemediated route enhances the therapeutic effect of DCA by a factor of 200. All three DCAcontaining samples were cytotoxic towards MCF-7 breast cancer cells, with the PEGylated MOF once again the most effective for delivery of DCA, and more effective for delivery of DCA than its UiO-66 analogue. The composition of Zr-fum was also expected to mediate immune system response, in addition to the small size decreasing macrophage uptake.
Surface modification did not notably change uptake of the MOFs by macrophage cells and had no effect on proliferation, while both empty and DCA-containing Zr-fum-L1-PEG2000 (s) did not induce significant ROS production; the bare sample induced the highest ROS production, with a 3-fold increase, which is less than observed for related UiO-66 nanoparticles. 28 Complement cascades (C3 and C4) in the blood plasma of three different human donors were not activated upon incubation with any of the empty or DCA-loaded MOFs, again showing good toleration of the nanoparticles by important immune system species.
Taken together, the improvement in both selective in vitro anticancer cytotoxicity and immune system compatibility compared to UiO-66 suggest Zr-fum is an excellent candidate for further investigation as a drug delivery device, with fine control over particle size and functionality possible. Additionally, the study highlights the in vitro experimental toolkit available to allow tuning of a range of properties of DDSs without invoking animal studies.
